Devyser Diagnostics AB (OSTO:DVYSR) Cash And Cash Equivalents : kr114.1 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Devyser Diagnostics AB Cash And Cash Equivalents?

Devyser Diagnostics AB's quarterly cash and cash equivalents declined from Sep. 2024 (kr171.40 Mil) to Dec. 2024 (kr144.50 Mil) but then stayed the same from Dec. 2024 (kr144.50 Mil) to Mar. 2025 (kr114.10 Mil).

Devyser Diagnostics AB's annual cash and cash equivalents declined from Dec. 2022 (kr363.60 Mil) to Dec. 2023 (kr262.90 Mil) and declined from Dec. 2023 (kr262.90 Mil) to Dec. 2024 (kr144.50 Mil).

Devyser Diagnostics AB Cash And Cash Equivalents Historical Data

The historical data trend for Devyser Diagnostics AB's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Devyser Diagnostics AB Cash And Cash Equivalents Chart

Devyser Diagnostics AB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

8.34

377.64

363.60

262.90

144.50

Devyser Diagnostics AB Quarterly Data
	Dec18	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash And Cash Equivalents	Get a 7-Day Free Trial															215.00	201.00	171.40	144.50	114.10

Devyser Diagnostics AB Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Devyser Diagnostics AB (OSTO:DVYSR) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Devyser Diagnostics AB Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Devyser Diagnostics AB's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Devyser Diagnostics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Devyser Diagnostics AB (OSTO:DVYSR) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

OL0:Germany

Address

Instrumentvagen 19, Hagersten, SWE, 126 53

Website

https://www.devyser.com

Devyser Diagnostics AB develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. The products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up.

Devyser Diagnostics AB Headlines

No Headlines